Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$821M |
| 2 |
AGN
Allergan plc
AGN
|
+$444M |
| 3 |
Apple
AAPL
|
+$304M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$301M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$251M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$839M |
| 2 |
Las Vegas Sands
LVS
|
+$405M |
| 3 |
Qualcomm
QCOM
|
+$402M |
| 4 |
Warner Bros
WBD
|
+$400M |
| 5 |
Perrigo
PRGO
|
+$357M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.61% |
| 2 | Consumer Discretionary | 14.39% |
| 3 | Communication Services | 12.98% |
| 4 | Technology | 11.5% |
| 5 | Energy | 10.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
451
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $16.2M | 0.02% |
642,005
+959
| +0.1% | +$25.3K |
|
|
ALDR
452
DELISTED
Alder Biopharmaceuticals
ALDR
| $16M | 0.01% |
1,262,087
+1,137,087
| +910% | +$17.2M |
|
|
CSII
453
DELISTED
Cardiovascular Systems, Inc.
CSII
| $16M | 0.01% |
675,670
+44,341
| +7% | +$1.26M |
|
|
FLXN
454
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $15.7M | 0.01% |
860,834
+40,157
| +5% | +$581K |
|
455
IMAX
IMAX
$2.6B
| $15.4M | 0.01% |
560,517
+18,808
| +3% | +$508K |
|
456
Monolithic Power Systems
MPWR
$61B
| $15.4M | 0.01% |
+348,883
| New | +$15.3M |
|
457
Marcus & Millichap
MMI
$1.21B
| $15.3M | 0.01% |
504,872
+37,099
| +8% | +$992K |
|
|
CMRX
458
DELISTED
Chimerix, Inc.
CMRX
| $15.3M | 0.01% |
553,129
-63,693
| -10% | -$1.55M |
|
459
Tempest Therapeutics
TPST
$14.5M
| $14.8M | 0.01% |
305
+80
| +36% | +$2.8M |
|
460
Agios Pharmaceuticals
AGIO
$2.08B
| $14.6M | 0.01% |
237,425
+186
| +0.1% | +$8.02K |
|
|
TFM
461
DELISTED
THE FRESH MARKET, INC COM STK
TFM
| $14.5M | 0.01% |
415,171
-286
| -0.1% | -$9.3K |
|
|
AVNR
462
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| $14.3M | 0.01% |
+1,200,000
| New | +$8.19M |
|
|
DATA
463
DELISTED
Tableau Software, Inc.
DATA
| $14.3M | 0.01% |
196,196
-19,755
| -9% | -$1.29M |
|
|
ACOR
464
DELISTED
Acorda Therapeutics
ACOR
| $14.2M | 0.01% |
3,499
+3
| +0.1% | +$11.3K |
|
|
FEIC
465
DELISTED
FEI COMPANY
FEIC
| $13.1M | 0.01% |
173,516
-201
| -0.1% | -$16.9K |
|
466
PUT
Alnylam Pharmaceuticals
ALNY
$38.2B
| $13M | 0.01% |
166,300
| – | – |
|
|
TTPH
467
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $12.9M | 0.01% |
32,406
+49
| +0.2% | +$13.1K |
|
|
MLU
468
DELISTED
METLIFE, INC. COM EQUITY UNIT
MLU
| $12.7M | 0.01% |
413,000
| – | – |
|
469
McEwen Inc
MUX
$975M
| $12.3M | 0.01% |
625,133
-9,418
| -1% | -$252K |
|
470
Douglas Emmett
DEI
$2.1B
| $12.2M | 0.01% |
475,430
-15,620
| -3% | -$439K |
|
|
PSXP
471
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $11.5M | 0.01% |
172,992
-27,983
| -14% | -$1.97M |
|
472
Asbury Automotive
ABG
$4.66B
| $11.5M | 0.01% |
178,830
+6,103
| +4% | +$421K |
|
473
PUT
Ionis Pharmaceuticals
IONS
$9.13B
| $11.1M | 0.01% |
285,000
| – | – |
|
474
Madrigal Pharmaceuticals
MDGL
$12.4B
| $11.1M | 0.01% |
104,968
+113
| +0.1% | +$15.7K |
|
475
United Natural Foods
UNFI
$3.07B
| $11M | 0.01% |
178,669
-257,012
| -59% | -$16.1M |
|
Similar funds
Jennison Associates's Q3 2014 Portfolio in Review
As of Q3 2014, Jennison Associates held 788 positions worth $108B, down 0.96% from $109B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q3 2014 filing shows 82 new, 334 increased, 281 reduced and 71 closed positions. Its largest new stake was Alibaba: 9,140,584 shares worth $812M. The largest sale was RTX Corp, an estimated $839M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q3 2014 buy was Alibaba: 9,140,584 shares worth $812M.
- Jennison Associates added most to Allergan plc in Q3 2014, an estimated $444M increase.
- Jennison Associates's biggest Q3 2014 reduction was Las Vegas Sands, cutting an estimated $405M.
- Jennison Associates fully exited RTX Corp in Q3 2014, selling an estimated $839M.
- Jennison Associates's ten largest holdings make up 20% of its $108B portfolio in Q3 2014.
- Jennison Associates opened 82 new positions and closed 71 in Q3 2014.
- Jennison Associates's portfolio value fell 0.96% quarter-over-quarter to $108B.
Based on Jennison Associates's 13F filing for Q3 2014, filed 5 Nov 2014.